Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression

Authors: Shih-Feng Cho, Yuli Christine Chang, Chao-Sung Chang, Sheng-Fung Lin, Yi-Chang Liu, Hui-Hua Hsiao, Jan-Gowth Chang, Ta-Chih Liu

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The pathogenesis of multiple myeloma involves complex genetic and epigenetic events. This study aimed to investigate the role and clinical relevance of the long non-coding RNA (lncRNA), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in multiple myeloma.

Methods

Bone marrow mononuclear cells were collected for analysis. The samples of multiple myeloma were taken from 45 patients at diagnosis, 61 post-treatment, and 18 who relapsed or had progression. Control samples were collected from 20 healthy individuals. Real-time quantitative reverse transcription polymerase chain reactions were performed to evaluate the expression of MALAT1. The clinical relevance of MALAT1 expression was also explored.

Results

MALAT1 was overexpressed in the newly diagnosed patients compared with post-treatment patients (mean ∆CT: -5.54 ± 0.16 vs. -3.84 ± 0.09, 3.25-fold change; p < 0.001) and healthy individuals (mean ∆CT: -5.54 ± 0.16 vs. -3.95 ± 0.21, 3.01-fold change; p < 0.001). The expression of MALAT1 strongly correlated with disease status, and the magnitude of change in MALAT1 post-treatment had prognostic relevance. The patients with early progression had a significantly smaller change in MALAT1 after treatment (mean ∆CT change: 1.26 ± 1.06 vs. 2.09 ± 0.79, p = 0.011). A cut-off value of the change in MALAT1 (∆CT change: 1.5) was obtained, and the patients with a greater decrease in MALAT1 (difference in ∆CT >1.5) had significantly longer progression-free survival compared with the patients with a smaller MALAT1 change (24 months vs. 11 months; p = 0.001). For the post-treatment patients, the risk of early progression could be predicted using this cut-off value.

Conclusions

MALAT1 was overexpressed in patients with myeloma and may play a role in its pathogenesis. In addition, MALAT1 may serve as a molecular predictor of early progression.
Appendix
Available only for authorised users
Literature
1.
Palumbo A, Anderson K: Multiple myeloma. N Engl J Med. 2011, 364: 1046-1060. 10.1056/NEJMra1011442.CrossRefPubMed
2.
Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM: A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009, 113: 5418-5422. 10.1182/blood-2008-12-195008.CrossRefPubMedPubMedCentral
3.
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009, 113: 5412-5417. 10.1182/blood-2008-12-194241.CrossRefPubMedPubMedCentral
4.
Kuehl WM, Bergsagel PL: Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002, 2: 175-187. 10.1038/nrc746.CrossRefPubMed
5.
Seidl S, Kaufmann H, Drach J: New insights into the pathophysiology of multiple myeloma. Lancet Oncol. 2003, 4: 557-564. 10.1016/S1470-2045(03)01195-1.CrossRefPubMed
6.
Bergsagel PL, Kuehl WM: Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005, 23: 6333-6338. 10.1200/JCO.2005.05.021.CrossRefPubMed
7.
Morgan GJ, Walker BA, Davies FE: The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012, 12: 335-348. 10.1038/nrc3257.CrossRefPubMed
8.
Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV: Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003, 17: 2025-2031. 10.1038/sj.leu.2403084.CrossRefPubMed
9.
Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI: Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004, 103: 3503-3510. 10.1182/blood-2003-07-2340.CrossRefPubMed
10.
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007, 7: 585-598. 10.1038/nrc2189.CrossRefPubMed
11.
Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, Rinn JL, Tongprasit W, Samanta M, Weissman S, Gerstein M, Snyder M: Global identification of human transcribed sequences with genome tiling arrays. Science. 2004, 306: 2242-2246. 10.1126/science.1103388.CrossRefPubMed
12.
International Human Genome Sequencing C: Finishing the euchromatic sequence of the human genome. Nature. 2004, 431: 931-945. 10.1038/nature03001.CrossRef
13.
14.
Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Muller-Tidow C: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003, 22: 8031-8041. 10.1038/sj.onc.1206928.CrossRefPubMed
15.
Guru SC, Agarwal SK, Manickam P, Olufemi SE, Crabtree JS, Weisemann JM, Kester MB, Kim YS, Wang Y, Emmert-Buck MR, Liotta LA, Spiegel AM, Boguski MS, Roe BA, Collins FS, Marx SJ, Burns L, Chandrasekharappa SC: A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus. Genome Res. 1997, 7: 725-735.PubMedPubMedCentral
16.
van Asseldonk M, Schepens M, de Bruijn D, Janssen B, Merkx G, Geurts van Kessel A: Construction of a 350-kb sequence-ready 11q13 cosmid contig encompassing the markers D11S4933 and D11S546: mapping of 11 genes and 3 tumor-associated translocation breakpoints. Genomics. 2000, 66: 35-42. 10.1006/geno.2000.6194.CrossRefPubMed
17.
Wilusz JE, Freier SM, Spector DL: 3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell. 2008, 135: 919-932. 10.1016/j.cell.2008.10.012.CrossRefPubMedPubMedCentral
18.
Friedel CC, Dolken L, Ruzsics Z, Koszinowski UH, Zimmer R: Conserved principles of mammalian transcriptional regulation revealed by RNA half-life. Nucleic Acids Res. 2009, 37: e115-10.1093/nar/gkp542.CrossRefPubMedPubMedCentral
19.
Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A: A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics. 2007, 8: 39-10.1186/1471-2164-8-39.CrossRefPubMedPubMedCentral
20.
Miyagawa R, Tano K, Mizuno R, Nakamura Y, Ijiri K, Rakwal R, Shibato J, Masuo Y, Mayeda A, Hirose T, Akimitsu N: Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles. RNA. 2012, 18: 738-751. 10.1261/rna.028639.111.CrossRefPubMedPubMedCentral
21.
Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe BJ, Prasanth SG, Prasanth KV: The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010, 39: 925-938. 10.1016/j.molcel.2010.08.011.CrossRefPubMedPubMedCentral
22.
Yang F, Yi F, Han X, Du Q, Liang Z: MALAT-1 interacts with hnRNP C in cell cycle regulation. FEBS Lett. 2013, 587: 3175-3181. 10.1016/j.febslet.2013.07.048.CrossRefPubMed
23.
Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Zhang Y, Gorospe M, Prasanth SG, Lal A, Prasanth KV: Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 2013, 9: e1003368-10.1371/journal.pgen.1003368.CrossRefPubMedPubMedCentral
24.
Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, Hillejan L, Wiebe K, Berdel WE, Wiewrodt R, Muller-Tidow C: The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011, 6: 1984-1992. 10.1097/JTO.0b013e3182307eac.CrossRefPubMed
25.
Xu C, Yang M, Tian J, Wang X, Li Z: MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol. 2011, 39: 169-175.PubMed
26.
Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F: Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012, 8: 2289-2294. 10.1039/c2mb25070e.CrossRefPubMed
27.
Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zornig M, MacLeod AR, Spector DL, Diederichs S: The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013, 73: 1180-1189. 10.1158/0008-5472.CAN-12-2850.CrossRefPubMed
28.
Lane L, Argoud-Puy G, Britan A, Cusin I, Duek PD, Evalet O, Gateau A, Gaudet P, Gleizes A, Masselot A, Zwahlen C, Bairoch A: neXtProt: a knowledge platform for human proteins. Nucleic Acids Res. 2012, 40: D76-83. 10.1093/nar/gkr1179.CrossRefPubMed
29.
Wu C, Macleod I, Su AI: BioGPS and MyGene.info: organizing online, gene-centric information. Nucleic Acids Res. 2013, 41: D561-565. 10.1093/nar/gks1114.CrossRefPubMed
30.
Isin M, Ozgur E, Cetin G, Erten N, Aktan M, Gezer U, Dalay N: Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta. 2014, 431: 255-259.CrossRefPubMed
31.
Chanan-Khan AA, Giralt S: Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010, 28: 2612-2624. 10.1200/JCO.2009.25.4250.CrossRefPubMed
32.
Moreau P, Attal M, Pegourie B, Planche L, Hulin C, Facon T, Stoppa AM, Fuzibet JG, Grosbois B, Doyen C, Ketterer N, Sebban C, Kolb B, Chaleteix C, Dib M, Voillat L, Fontan J, Garderet L, Jaubert J, Mathiot C, Esseltine D, Avet-Loiseau H, Harousseau JL, investigators IFMs: Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2011, 117: 3041-3044. 10.1182/blood-2010-08-300863.CrossRefPubMed
Metadata
Title
MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression
Authors
Shih-Feng Cho
Yuli Christine Chang
Chao-Sung Chang
Sheng-Fung Lin
Yi-Chang Liu
Hui-Hua Hsiao
Jan-Gowth Chang
Ta-Chih Liu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-809

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation

Correspondence

The randomised clinical trial and the hazard ratio – medical research’s Emperor’s New Clothes?

Research article

Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study

Research article

Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance

Research article

Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer

Research article

Population-based incidence trends of oropharyngeal and oral cavity cancers by sex among the poorest and underprivileged populations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits